Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Aldosterone Synthase Inhibition in Diabetes and Cardiorenal Metabolic Disease.

Journal of diabetes·2026
Same author

Cardiovascular Disease, Cancer and Dementia in Diabetes: 20-Year Trends Will Necessitate New Treatment Priorities.

Journal of diabetes·2026
Same author

Beyond GLP-1.

Journal of diabetes·2026
Same author

Updates in Type 1 Diabetes (T1D): What Recent Findings Might Mean for Treatment and Prevention Strategies.

Journal of diabetes·2026
Same author

Diabetes and the Retina: The Role of Medical Treatment.

Journal of diabetes·2025
Same author

Recent Articles-Skeletal Muscle and Other Topics in Diabetes.

Journal of diabetes·2025

Related Experiment Video

Updated: Jul 9, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review.

Zachary Bloomgarden1

  • 1Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Journal of Diabetes
|July 8, 2026
PubMed
Summary

Real-world incretin therapies show effectiveness similar to clinical trials when patients reach target doses. However, high discontinuation rates impact outcomes, especially for obesity and type 2 diabetes management.

Related Experiment Videos

Last Updated: Jul 9, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Clinical Research

Background:

  • Incretin-based therapies have significantly advanced obesity and type 2 diabetes (T2D) treatment.
  • Randomized controlled trials (RCTs) demonstrate substantial weight loss and glycemic control with these agents.
  • The translation of RCT efficacy to real-world clinical practice remains an area of investigation.

Purpose of the Study:

  • To compare the effectiveness of incretin-based therapies in real-world settings versus pivotal RCTs.
  • To analyze weight loss, HbA1c reduction, and major adverse cardiovascular events (MACE) in diverse patient populations.
  • To identify factors influencing the observed efficacy gap between trial and real-world data.

Main Methods:

  • A descriptive comparison of seven meta-analyses from 2026 RCTs (58,976 participants) with 26 real-world studies.
  • PubMed search utilized for identifying real-world studies on semaglutide and tirzepatide.
  • Primary outcomes: body weight loss and HbA1c reduction; Secondary outcomes: MACE, neurological events, and safety.

Main Results:

  • Real-world T2D patients on semaglutide showed lower weight loss (4.7-10.5 kg) and HbA1c reduction (1.0-1.3 pp) than RCT estimates.
  • In non-diabetic populations, real-world 'persister' analyses approximated RCT per-protocol estimates, but intention-to-treat data were lower.
  • Low dose attainment rates (semaglutide 2.4 mg: 13%; tirzepatide 15 mg: 25.9%) and high discontinuation (20-50% yearly) were observed.

Conclusions:

  • Real-world incretin therapy effectiveness aligns with RCT efficacy when dose attainment and patient persistence are considered.
  • Differences in real-world vs. RCT outcomes are likely due to channeling bias, differential follow-up, and adherence.
  • Further head-to-head cardiovascular outcome trials comparing tirzepatide and semaglutide in non-diabetic populations are warranted.